drugset / Trial / NCT01969357
A Study of the Effectiveness and Safety of SP2086 to Treat Type 2 Diabetes
RandomizedParallel-groupQuadruple-blindTreatment
Summary
SP2086 is a new dipeptidy1 peptidase(DPP)-4 inhibitors. This study aims to explore the effective dose range of SP2086 in Patients with type 2 diabetes.
Timeline
- Start
- 2011-06
- Primary completion
- 2012-04
- Completion
- 2012-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Retagliptin | Small molecule | 50 mg | — |
| Subject | Retagliptin | Small molecule | 100 mg | — |
| Subject | Retagliptin | Small molecule | 200 mg | — |
| Comparator | Sitagliptin | Small molecule | 100 mg | — |